Back to top
more

Pacific Biosciences of California (PACB)

(Delayed Data from NSDQ)

$1.87 USD

1.87
8,738,636

-0.07 (-3.61%)

Updated May 24, 2024 03:59 PM ET

After-Market: $1.88 +0.01 (0.53%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (144 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Pacific Biosciences of California (PACB) Reports Break-Even Earnings for Q4

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 100.00% and 9.79%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Pacific Biosciences Stock Now

Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.

Pacific Biosciences (PACB) Up 2.7% Since Last Earnings Report: Can It Continue?

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold on to Pacific Biosciences Stock

Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.

Options Traders Expect Huge Moves in Pacific Biosciences (PACB) Stock

Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately.

Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates

Pacific Biosciences (PACB) gains from solid segmental contributions in the third quarter.

Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates

Pacific Biosciences (PACB) delivered earnings and revenue surprises of -26.67% and -21.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Pacific Biosciences of California (PACB) Report Negative Q3 Earnings? What You Should Know

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Pacific Biosciences For Now

Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, contraction in gross margin remains a woe.

Why Is Pacific Biosciences (PACB) Up 0.2% Since Last Earnings Report?

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pacific Biosciences (PACB) Beats on Q2 Earnings & Revenues

Pacific Biosciences (PACB) Q2 results gain from higher revenues and strong segmental performance. Contraction in gross margin remains a woe.

Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 11.11% and 10.58%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Pacific Biosciences of California (PACB) to Report a Decline in Earnings: What to Look Out for

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health

The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health

Kevin Cook headshot

46 and You: Genetic Testing = Giant Growth Market

Advances in genomic diagnostic technology have made testing affordable for the 99.0% of the world still in line.

Pacific Biosciences (PACB) Down 7.8% Since Last Earnings Report: Can It Rebound?

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pacific Biosciences (PACB) Incurs Loss in Q1, Revenues Fall

Pacific Biosciences' (PACB) segments see softness in Q1; merger with Illumina on track.

Will Pacific Biosciences of California (PACB) Report Negative Q1 Earnings? What You Should Know

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pacific Biosciences (PACB) Up 3.8% Since Last Earnings Report: Can It Continue?

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pacific Biosciences (PACB) Incurs Q4 Loss, Revenues Fall Y/Y

Pacific Biosciences' (PACB) dismal fourth-quarter 2018 results can be attributed to disappointing performance by the company's Product Revenue segment.

Pacific Biosciences of California (PACB) Reports Q4 Loss, Lags Revenue Estimates

Pacific Biosciences (PACB) delivered earnings and revenue surprises of -61.54% and -7.37%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LMNX or PACB: Which is a Better MedTech Investment Pick?

Luminex (LMNX) scores higher than Pacific Biosciences (PACB) considering growth projections and fundamentals.

Here's Why You Should Hold Pacific Biosciences (PACB) Now

Pacific Biosciences (PACB) is likely to gain from strong prospects in the Sequel System platform. However, the company faces cutthroat competition in the DNA sequencing market.